172168-01-3

Basic information

• Product Name: 3-(3,5-DICHLOROPHENYL)-3-OXO-PROPIONIC ACID ETHYL ESTER
• Synonyms: ETHYL (3,5-DICHLOROBENZOYL)ACETATE;3-(3,5-DICHLOROPHENYL)-3-OXO-PROPIONIC ACID ETHYL ESTER;ETHYL 3-(3,5-DICHLOROPHENYL)-3-OXOPROPANOATE;Benzenepropanoic acid, 3,5-dichloro-b-oxo-, ethyl ester;3-(3,5-Dichlorophenyl)-3-oxo-propionic acid ethyl este
• CAS NO: 172168-01-3
• Molecular Formula: C₁₁H₁₀Cl₂O₃
• Molecular Weight: 261.1
• Mol File: 172168-01-3.mol

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 3-(3,5-DICHLOROPHENYL)-3-OXO-PROPIONIC ACID ETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(3,5-DICHLOROPHENYL)-3-OXO-PROPIONIC ACID ETHYL ESTER(172168-01-3)
• EPA Substance Registry System: 3-(3,5-DICHLOROPHENYL)-3-OXO-PROPIONIC ACID ETHYL ESTER(172168-01-3)

Safety Data

• Hazardous Substances Data: 172168-01-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
3-(3,5-Dichlorophenyl)-3-oxo-propionic acid ethyl ester is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its incorporation into drug molecules can enhance their therapeutic properties, such as potency, selectivity, and bioavailability.
Used in Agrochemical Production:
In the agrochemical industry, 3-(3,5-Dichlorophenyl)-3-oxo-propionic acid ethyl ester serves as a crucial building block for the development of new pesticides and herbicides. Its chemical structure contributes to the effectiveness of these products in controlling pests and weeds, thereby increasing crop yields and protecting agricultural investments.
Used as a Reagent in Organic Synthesis:
3-(3,5-Dichlorophenyl)-3-oxo-propionic acid ethyl ester is utilized as a reagent in organic synthesis to introduce the desired 3-(3,5-dichlorophenyl)-3-oxo-propionic acid functional group into target molecules. This allows for the creation of a diverse range of organic compounds with specific properties and applications in various fields, including materials science, medicinal chemistry, and specialty chemicals.

Upstream product

• 91085-56-2 3,5-dichlorobenzoic acid ethyl ester 
• 141-78-6 ethyl acetate 
• 2905-62-6 3,5-dichlorobenzoyl chloride 
• 1071-46-1 hydrogen ethyl malonate 

Downstream Products

• 870822-95-0 ethyl 4-{1-[3-(3,5-dichlorophenyl)-5-oxo-4,5-dihydro-1H-pyrazol-1-yl]ethyl}benzoate 

Relevant articles and documents

Design, synthesis, structure-activity relationships, and docking studies of pyrazole-containing derivatives as a novel series of potent glucagon receptor antagonists

Glucagon receptor antagonists possess a great potential for treatment of type 2 diabetes mellitus. A series of pyrazole-containing derivatives were designed, synthesized and evaluated by biological assays as glucagon receptor antagonists. Most of the compounds exhibited good in vitro efficacy. Two of them, compounds 17f and 17k, displayed relatively potent antagonist effects on glucagon receptors with IC50 values of 3.9 and 3.6 μM, respectively. The possible binding modes of 17f and 17k with the cognate receptor were explored by molecular docking simulation.

Thrombin receptor antagonists

A thrombin receptor antagonist having the formula useful for inhibiting the aggregation of blood platelets. The compounds can be used in a method of acting upon a thrombin receptor which comprises administering a therapeutically effective but non-toxic am

Synthesis and pharmacological evaluation of a new series of substituted benzoyl-γ-butyrolactone derivatives

A series of substituted benzoyl-γ-butyrolactones (1-3) has been synthesized and tested for their ability to affect central dopaminergic and GABAergic function in comparison to γ-butyrolactone (GBL).Similarly to GBL, α-, β- and γ-substituted GBLs 1-3 with one or more chlorine on the phenyl ring were found to induce central depressant effects in rats, though at different degrees.However, the test compounds modified dopamine (DA) metabolism in rat striatum differently from GBL.In fact, whereas GBL increased both DA and dihydroxyphenylacetic acid (DOPAC) content, GBL derivatives 1-3 increased DA levels, but reduced the DOPAC concentration.Moreover, some of them, unlike GBL, effectively antagonized pentylenetetrazole (PTZ)-induced seizures in mice.In particular, α-3,5-dichlorobenzoyl-GBL (1g) was effective at a dose as low a 36 mg/kg in decressing the number of animals having convulsions.However, in vitro addition and in vivo administration of the test compounds failed to modify -t-butylbicyclophosphorothionate (-TBPS) binding, which is a very sensitive tool for revealing changes in the GABAergic function. γ-butyrolactone / benzoyl-γ-butyrolactone / dopamine / anticonvulsant effect